Pin Therapeutics
June 16, 2025
Company Presentation
Platform for Therapeutics
Pin Therapeutics was founded in South Korea in 2018. We are an innovative biotech company developing a targeted protein degradation platform focused on novel E3 ligases (PinE3) and molecular glue degraders (MGDs). Our expertise lies in next-generation E3 ligases beyond CRBN and VHL, called PinE3. The most advanced and validated program, Ligase 2 platform, exhibits heme-sparing characteristics, suggesting broad therapeutic potential. One of the key pipelines derived from this is Ligase 2-based KRAS degrader. Additionally, we have developed promising degrader payloads applicable to ADCs using Ligase 2.
Beyond this, our lead pipeline is a CK1α-selective MGD, for which we plan to submit an IND in Mar–Apr 2025 for the treatment of solid tumors.
We are committed to developing advanced protein degradation therapeutics by focusing on diverse disease areas while targeting various proteins, and establishing a range of collaborative models with pharmaceutical companies.
Company HQ City:
Seongnam-si
Company HQ State:
Gyeonggi-do
Company HQ Country:
Korea, Republic of
Year Founded:
2018
Lead Product in Development:
PIN-5018, CK1a-selective molecular glue degrader
CEO
Hyunsun Jo
Year Founded
2018
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
- at least 3 pipelines in discovery - pre-clinical stage
- 1 platform technology (targeting platform-based multi-target deals)
When you expect your next catalyst update?
- PIN-5018: US FDA IND submission and open
- PIN-5018: Phase 1a study initiation & clinical site open
- Bridging funding (or pre-IPO funding)
What is your next catalyst (value inflection) update?
- PIN-5018: US FDA IND submission and open: 2025 Q2
- PIN-5018: Phase 1a study initiation & clinical site open: 2025 Q3
- Bridging funding (or pre-IPO funding): 2025 Q4
Website
https://www.pintherapeutics.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}